Recently, scientists at the Center for Infectious Diseases Research at the University of Adelaide in Australia have developed a single vaccination method. It can simultaneously fight two of the world’s deadliest respiratoryRead More…
Johnson (JNJ) of the United States recently announced that patients who evaluated the IIb phase proof-of-concept efficacy study Imbokodo (HVTN 705/HPX2008) of a prophylactic HIV vaccine have been enrolled. The study isRead More…
Thousands of people die of hepatitis B every year. Children are especially in danger. Because of the high cost and stable environmental conditions required for vaccine storage, many people in developing countriesRead More…
In a recent study, Cornell University researchers developed a new class of biomaterials for an infectious disease, nanovaccines, which can effectively improve the immunity of mice with metabolic disorders associated with intestinalRead More…
For years, scientists have been trying to come up with a better way to protect people from mycobacterium tuberculosis, a disease caused by Mycobacterium tuberculosis (Mtb) infection. Dr. Jordi Torrelles, a professorRead More…
The Inovio Pharmaceuticals recently announced that a second patient with human papillomavirus (HPV) head and neck cancer has achieved sustained complete remission in the first phase of the trial after INO-3112 (nowRead More…
Sanofi has announced that the FDA has approved Vaxelis, a full-liquid ready-to-use hexavalent combination vaccine for infants from 6 weeks old to 4 years old (before the 5th birthday). The vaccine isRead More…
In a recent study published in Science Advances, scientists from the Scripps Research Institute overcame technical hurdles to develop a new HIV vaccine candidate that stimulates the body to produce a powerfulRead More…
Sanofi, a French pharmaceutical giant, recently announced that the US Food and Drug Administration (FDA) has accepted the dengue vaccine Dengvaxia’s Biologics License Application (BLA) and granted priority review. The vaccine isRead More…